Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics
Caladrius Biosciences Inc (NASDAQ:CLBS) and privately-held Cend Therapeutics Inc have agreed to merge in an all-stock approximate "merger of equals" transaction approved by the Boards of Directors of each company. The transaction values each company at $90 million, which for Caladrius represents a 136% premium to its market cap on April 26. Following closing, the…
Benzinga ·
Benzinga
